Mutational activation of the MAP3K8 protooncogene in lung cancer

被引:47
作者
Clark, AM
Reynolds, SH
Anderson, M
Wiest, JS
机构
[1] NCI, Cellular Carcinogenesis & Tumor Promot Lab, Canc Res Ctr, Bethesda, MD 20892 USA
[2] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA
[3] NIOSH, Morgantown, WV 26505 USA
关键词
D O I
10.1002/gcc.20069
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The MAP3K8 protooncogene (Cot/Tpl-2) activates the MAP kinase, SAP kinase, and NF-kappaB signaling pathways. MAP3K8 mutations occur in the rat homologue, but activating mutations have yet to be identified in primary human tumors. We have identified MAP3K8 as a transforming gene from a human lung adenocarcinoma and characterized a 3' end mutation in the cDNA. In addition, we confirmed that the mutation occurs in the original lung tumor, and we screened a series of lung cancer cell lines to determine whether the MAP3K8 mutation is a common occurrence in lung tumorigenesis. The oncogene was isolated and identified with the NH3T3 nude mouse turnorigenicity assay and cDNA library screening. The gene was analyzed by polymerase chain reaction (PCR), single-strand conformational polymorphism (SSCP), and 3'RACE for mutations. The mutation was localized to MAP3K8 exon 8 and confirmed in the primary tumor DNA. Both wild-type and mutant MAP3K8 cDNAs transformed NIH3T3 cells, but the transforming activity of the mutant was much greater than that of the wild type. PCR-SSCP screening of cell line cDNAs identified one silent polymorphism in cell line SK-LU-1. Although we were unable to find additional activating mutations, these data support a role for MAP3K8 activity in cellular transformation, but suggest that mutational activation of the gene is a rare event in lung cancer. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 34 条
  • [1] AOKI M, 1991, ONCOGENE, V6, P1515
  • [2] AOKI M, 1993, J BIOL CHEM, V268, P22723
  • [3] Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines
    Bansal, A
    Ramirez, RD
    Minna, JD
    [J]. ONCOGENE, 1997, 14 (10) : 1231 - 1234
  • [4] NF-κB1 p105 negatively regulates TPL-2 MEK kinase activity
    Beinke, S
    Deka, J
    Lang, V
    Belich, MP
    Walker, PA
    Howell, S
    Smerdon, SJ
    Gamblin, SJ
    Ley, SC
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (14) : 4739 - 4752
  • [5] TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105
    Belich, MP
    Salmerón, A
    Johnston, LH
    Ley, SC
    [J]. NATURE, 1999, 397 (6717) : 363 - 368
  • [6] Oncogenic kinase signalling
    Blume-Jensen, P
    Hunter, T
    [J]. NATURE, 2001, 411 (6835) : 355 - 365
  • [7] Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants
    Brognard, J
    Dennis, PA
    [J]. CELL DEATH AND DIFFERENTIATION, 2002, 9 (09) : 893 - 904
  • [8] Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation
    Ceci, JD
    Patriotis, CP
    Tsatsanis, C
    Makris, AM
    Kovatch, R
    Swing, DA
    Jenkins, NA
    Tsichlis, PN
    Copeland, NG
    [J]. GENES & DEVELOPMENT, 1997, 11 (06) : 688 - 700
  • [9] CHAN AML, 1993, ONCOGENE, V8, P1329
  • [10] Multiple mitogen-activated protein kinase signaling pathways connect the Cot oncoprotein to the c-jun promoter and to cellular transformation
    Chiariello, M
    Marinissen, MJ
    Gutkind, JS
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (05) : 1747 - 1758